www.ft.com

www.ft.com
Share

www.ft.com

 •  October 10

Pfizer said it was looking to sell or spin off its consumer healthcare business in a move that could fetch up to $14bn of cash for the pharmaceuticals group and set off a flurry of dealmaking. The drugmaker said it was considering a range of options for the business, which makes Centrum vitamins and ChapStick lip balm, including “a full or partial...

www.ft.com

 •  August 29

Gilead Sciences has reached an $11.9bn agreement to acquire Kite Pharma, adding a cutting edge cancer treatment to its portfolio and ending the biotech company’s long search for a sizeable deal. The California-based biotech group will pay $180 in cash per share for Kite, which makes an experimental treatment that re-engineers a patient’s white...

www.ft.com

 •  April 18

In 2012, the London Declaration on neglected tropical diseases targeted 10 of the 17 diseases then prioritised by the World Health Organisation. The hope among the drugmakers, government agencies and aid groups that signed the declaration was that these diseases would be classed as “under control” by 2020, with lymphatic filariasis, blinding...

www.ft.com

 •  February 14

The pharmaceuticals sector has been gripped by a mergers and acquisitions frenzy for the best part of two years, with some of the biggest names in the industry fighting over hot new drugs. Last year was a record for dealmaking in the sector and 2015 is also off to a strong start, with healthcare transactions worth $193.9bn announced since the...

www.ft.com

 •  February 14

This article is provided to FT.com readers by BioPharm Insight—a news service focused on providing insight into the most price sensitive issues in the global pharmaceutical market. www.biopharminsight.com -------------------------------------------------------------------------------- Shire (LON:SHP), Vertex Pharmaceuticals (NASDAQ:VRTX) and...